Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Acurx Pharmaceuticals develops novel small molecule antibiotics targeting Gram-positive bacterial infections, focusing on DNA polymerase IIIC inhibition. Its lead candidate, ibezapolstat, addresses Clostridioides difficile infections with a unique mechanism that preserves beneficial gut microbiota and reduces recurrence. The company’s pipeline also targets resistant pathogens like MRSA and VRE. Acurx operates in the antimicrobial resistance sector, aiming to provide safer, effective treatments for serious bacterial infections through clinical-stage drug development.
This description was generated via AI from an annual report. Updated about 1 year ago.